Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Galli

Showing results (61-70 of 217) with videos related to

Pageof 22
Sort By:
Psychiatria Danubina|November 23, 2023
The Life Project of People with Autism and Intellectual Disability: Investigating Personal Preferences and Values to Enhance Self-DeterminationSerafino Corti, Roberto Cavagnola, Davide Carnevali, et al.
The New Microbiologica|April 21, 2020
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infectionFrancesca Rinaldi, Serena Rolla, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infectionSilvia Nozza, Andrea Poli, Marco Ripa, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' responseSilvia Nozza, Andrea Poli, Marco Ripa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2023
Risk of Cardiovascular Diseases or Mortality in People With Higher Values of HIV-1 DNAMartina Bottanelli, Daniele Ceccarelli, Riccardo Lolatto, et al.
Steroids|February 21, 2015
7-Ketocholesterol and 5,6-secosterol induce human endothelial cell dysfunction by differential mechanismsFrancesca Luchetti, Barbara Canonico, Erica Cesarini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
European Journal of Endocrinology|March 29, 2007
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsMonica Guffanti, Andrea Caumo, Laura Galli, et al.
Therapeutics and Clinical Risk Management|January 1, 2014
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital settingGiorgio L Colombo, Antonella Castagna, Sergio Di Matteo, et al.
Infectious Diseases (London, England)|September 12, 2017
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL studyLaura Galli, Andrea Poli, Camilla Muccini, et al.
Pageof 22

Showing results (61-70 of 217) with videos related to

Sort By:
Pageof 22
Psychiatria Danubina|November 23, 2023
The Life Project of People with Autism and Intellectual Disability: Investigating Personal Preferences and Values to Enhance Self-DeterminationSerafino Corti, Roberto Cavagnola, Davide Carnevali, et al.
The New Microbiologica|April 21, 2020
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infectionFrancesca Rinaldi, Serena Rolla, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infectionSilvia Nozza, Andrea Poli, Marco Ripa, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' responseSilvia Nozza, Andrea Poli, Marco Ripa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2023
Risk of Cardiovascular Diseases or Mortality in People With Higher Values of HIV-1 DNAMartina Bottanelli, Daniele Ceccarelli, Riccardo Lolatto, et al.
Steroids|February 21, 2015
7-Ketocholesterol and 5,6-secosterol induce human endothelial cell dysfunction by differential mechanismsFrancesca Luchetti, Barbara Canonico, Erica Cesarini, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
European Journal of Endocrinology|March 29, 2007
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsMonica Guffanti, Andrea Caumo, Laura Galli, et al.
Therapeutics and Clinical Risk Management|January 1, 2014
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital settingGiorgio L Colombo, Antonella Castagna, Sergio Di Matteo, et al.
Infectious Diseases (London, England)|September 12, 2017
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL studyLaura Galli, Andrea Poli, Camilla Muccini, et al.
Pageof 22